Germany-based Ovom Care has raised €4.8 million in seed funding led by Alpha Intelligence Capital and supported by Ananda Impact Ventures and Merantix. The company combines hybrid reproductive care with advanced AI solutions, aiming to improve patient outcomes and expand fertility access to women at more affordable rates.
To date Ovom Care has treated over 100 patients in its London clinic and will use the fresh funds to finance the expansion of its services across Europe. Ovom Care plans to open its first clinic in Portugal toward the end of 2024. The investment will also accelerate enhancements to Ovom’s AI platform, broaden service offerings, and support ongoing research to deepen understanding of reproductive health. Ovom Care leverages historical and real-time patient data to train algorithms, which serve as medical decision support tools for clinicians and embryologists. This approach enables improved outcomes and dynamic pricing, thereby alleviating financial risks for patients undergoing fertility treatment.
“I believe we’re on the brink of a revolution in fertility care.” said Felicia von Reden, Co-founder and CEO. “I’m proud to spearhead this transformative journey together with my two co-founders Dr. Lynae Brayboy and Dr. Cristina Hickman. We are dedicated to defining a new era in reproductive care empowering every human that seeks to build a family to become a parent. Our mission is threefold: drastically improving treatment success rates, increasing accessibility, and driving patient centricity and convenience along the fertility journey.”
Terry Chou, partner at Alpha Intelligence Capital, said, “Before investing in Ovom Care, we have spent the year comparing various AI-enabled fertility solutions and assessment tools. Ovom being a digital-first AI-enabled clinic, has provided a great platform for different AI-powered fertility solutions to bring together their value, a collective intelligence revolutionising the reproductive care space”
Mascha Bonk, Investment Manager at Ananda Impact Ventures, states: “Globally, 17.5% of the adult population – roughly 1 in 6 – experience infertility. For many, in vitro fertilisation (IVF) represents a beacon of hope on their journey to becoming a parent but presents considerable financial and emotional challenges, with treatment costs ranging from EUR 15-30k and success rates hovering around 35%. With their revolutionary approach, Ovom Care is making treatments more successful, accessible, and patient-friendly. We are proud to support Ovom Care in their journey to build a future where family becomes a possibility for everyone.”
